MTOR and diffuse large B-cell lymphoma: Our results suggest simultaneous PI3Kβ/δ blockade would not only markedly increase the efficacy of mTOR inhibitors but would also sensitize mTOR or PI3Kβ/δ inhibitor-resistant cells to the treatment, independent of their DLBCL classification.